in an attempt to improve upon the 43 % -48 % regression rates noted for various cap regimens consisting of cyclophosphamide , doxorubicin ( adriamycin ) , and cis-diamminedichloroplatinum ( ii ) in various doses and schedules , triazinate was added to that three-drug combination , and the new combination ( t-cap ) was evaluated in patients with advanced adenocarcinoma of the lung .
C0010583
cyclophosphamide
C0279271
t-cap